Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.019 | 1 | 1 |
Mycobacterium tuberculosis | Probable protease II PtrBa [first part] (oligopeptidase B) | 0.0123 | 0.5067 | 1 |
Trypanosoma brucei | prolyl endopeptidase | 0.0138 | 0.6135 | 1 |
Onchocerca volvulus | 0.019 | 1 | 1 | |
Toxoplasma gondii | prolyl endopeptidase | 0.0138 | 0.6135 | 0.5 |
Onchocerca volvulus | 0.0173 | 0.875 | 0.6767 | |
Leishmania major | prolyl oligopeptidase, putative,serine peptidase clan SC, family S9A, putative | 0.0138 | 0.6135 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.019 | 1 | 1 |
Echinococcus granulosus | prolyl endopeptidase | 0.0138 | 0.6135 | 0.5 |
Mycobacterium ulcerans | protease II (oligopeptidase B), PtrB | 0.0055 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE PROTEASE II PTRBB (OLIGOPEPTIDASE B) | 0.0055 | 0 | 0.5 |
Echinococcus multilocularis | prolyl endopeptidase | 0.0138 | 0.6135 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.019 | 1 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.019 | 1 | 1 |
Trypanosoma cruzi | prolyl endopeptidase | 0.0138 | 0.6135 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 2.3 uM | Resistance index for cisplatin-resistant A2780 human ovarian adenocarcinoma cell line to that of A2780 cell line | ChEMBL. | 15689170 |
IC50 (functional) | = 167.86 uM | Inhibitory concentration of the compound against human A2780 ovarian adenocarcinoma cell line | ChEMBL. | 15689170 |
IC50 (functional) | = 385.98 uM | Inhibitory concentration of the compound against cisplatin-resistant A2780 human ovarian adenocarcinoma cell line | ChEMBL. | 15689170 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.